COST-EFFECTIVENESS OF BUDESONIDE CONTROLLED ILEAL RELEASE (CIR) CAPSULES AS MAINTENANCE THERAPY VERSUS NO MAINTENANCE THERAPY FOR ILEOCECALCROHNS-DISEASE IN SWEDEN

Citation
I. Noble et al., COST-EFFECTIVENESS OF BUDESONIDE CONTROLLED ILEAL RELEASE (CIR) CAPSULES AS MAINTENANCE THERAPY VERSUS NO MAINTENANCE THERAPY FOR ILEOCECALCROHNS-DISEASE IN SWEDEN, Clinical drug investigation, 15(2), 1998, pp. 123-136
Citations number
45
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pharmacology & Pharmacy
Journal title
ISSN journal
1173-2563
Volume
15
Issue
2
Year of publication
1998
Pages
123 - 136
Database
ISI
SICI code
1173-2563(1998)15:2<123:COBCIR>2.0.ZU;2-Z
Abstract
A decision-analytic model was designed to estimate the associated cost s and outcomes of maintenance therapy for Crohn's disease with budeson ide controlled ileal release (CIR) capsules (Entocort(R) capsules, Ast ra Draco, Lund, Sweden) versus no maintenance therapy. A third-party p ayer perspective was adopted to compare the direct costs associated wi th the medication and healthcare resource use for each therapy over a period of 12 four-week cycles. The costs of routine patient care and t he consequences of failure, in terms of relapses, acute therapies, hos pitalisations and surgery, were included. The outcome was measured as the average number of days in remission per patient per 12-cycle perio d. Based on the assumptions in the model, the results show that budeso nide CIR capsules are associated with a reduction of 16.6 (26%) days i n relapse, i.e. a 6% increase in days in remission, over a one-year pe riod compared with no maintenance therapy. Direct healthcare costs are increased by 6% or Swedish kronor (SEK) 1673 ($US1 similar to SEK7.60 ). Overall, the model shows that there are substantial (non-drug assoc iated) cost offsets from using budesonide CIR capsules as maintenance therapy in Crohn's disease. These cost offsets, in addition to improve ments in patients' well-being and quality of life, indicate that maint enance therapy is cost effective compared with no maintenance therapy. The cost per added day in remission is relatively modest (SEK101 simi lar to $US13). If indirect costs are added to the calculation, it is r ealistic to argue that a net saving to society would be most likely.